| 產(chǎn)品名稱(chēng) | CLN H11.4 |
|---|---|
| 商品貨號(hào) | B164268 |
| Organism | human (B cell); human (myeloma) |
| Cell Type | hybridoma: B lymphocyte |
| Product Format | frozen |
| Morphology | lymphoblast |
| Culture Properties | suspension |
| Biosafety Level | 2 Cells contain EBV viral nucleic acid sequences
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | a regional draining lymph node of a patient with squamous cell carcinoma of the cervix.,a regional draining lymph node of a patient with squamous cell carcinoma of the cervix. |
| Applications | The antibody reacted with carcinomas of the cervix (CaSki, HeLa), prostate (PC-3), breast (ZR-76-1), colon (COLO-205) and melanoma (G-361) but was negative for normal fibroblasts (WI-38 and MRC-9), T. lymphocytes and peripheral blood lymphocytes. The antibody may be useful in therapy and diagnosis, both in vitro and in vivo. |
| Storage Conditions | liqid nitrogen vapor temperature |
| Disclosure | This material is cited in a US or other Patent and may not be used to infringe the claims. Depending on the wishes of the Depositor, ATCC may be required to inform the Patent Depositor of the party to which the material was furnished. This material may not have been produced or characterized by ATCC. |
| Derivation | Lymphocytes were isolated from a regional draining lymph node of a patient with squamous cell carcinoma of the cervix. B lymphocytes were fused with UC 729-6 cells (see ATCC CRL-8061). |
| Clinical Data | Lymphocytes were isolated from a regional draining lymph node of a patient with squamous cell carcinoma of the cervix. The antibody may be useful in therapy and diagnosis, both in vitro and in vivo. |
| Genes Expressed | immunoglobulin; monoclonal antibody; against human cervical carcinoma |
| Cellular Products | immunoglobulin; monoclonal antibody; against human cervical carcinoma |
| Comments | The fusion line, CRL-8061, is reported to be EBNA positive. Lymphocytes were isolated from a regional draining lymph node of a patient with squamous cell carcinoma of the cervix. B lymphocytes were fused with UC 729-6 cells (see ATCC CRL-8061). The antibody reacted with carcinomas of the cervix (CaSki, HeLa), prostate (PC-3), breast (ZR-76-1), colon (COLO-205) and melanoma (G-361) but was negative for normal fibroblasts (WI-38 and MRC-9), T. lymphocytes and peripheral blood lymphocytes. The antibody may be useful in therapy and diagnosis, both in vitro and in vivo. |
| Complete Growth Medium | The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing | Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation | Freeze medium: Complete growth medium 95%; DMSO, 5% Storage temperature: liqid nitrogen vapor temperature |
| Culture Conditions | Temperature: 37.0°C |
| Isotype | IgG1; kappa light chain; human
Ref  Aotsuka Y, Hagiwara H. Identification of a malignant cell associated antigen recognized by a human monoclonal antibody. Eur. J. Cancer Clin. Oncol. 24: 829-838, 1988. PubMed: 3049115 |
| Name of Depositor | Gildred Cancer Center |
| U.S. Patent Number | |
| References | Handley HH, et al. Methods of determining the presence of a neoplasm with CLNH5- and CLNH11-specific antibodies. US Patent 6,051,387 dated Apr 18 2000 Handley HH, et al. Human-human hybridom for neoplasms CLNH5 and CLNH11 specific antibody compositions. US Patent 6,051,229 dated Apr 18 2000 Handley HH, et al. CLNH11-specific antibodies. US Patent 6,051,693 dated Apr 18 2000 Hagiwara H, Sato GH. Human X human hybridoma producing monoclonal antibody against autologous cervical carcinoma. Mol. Biol. Med. 1: 245-252, 1983. PubMed: 6334217 Aotsuka Y, Naito M. Enhancing effects of retinoic acid on monoclonal antibody production of human-human hybridomas. Cell. Immunol. 133: 498-505, 1991. PubMed: 2015633 Aotsuka Y, Hagiwara H. Identification of a malignant cell associated antigen recognized by a human monoclonal antibody. Eur. J. Cancer Clin. Oncol. 24: 829-838, 1988. PubMed: 3049115 Aotsuka Y, Hagiwara H. Identification of a malignant cell associated antigen recognized by a human monoclonal antibody. Eur. J. Cancer Clin. Oncol. 24: 829-838, 1988. PubMed: 3049115 |
| 序號(hào) | 文章標(biāo)題 | 操作 |
|---|---|---|
| 1 | ATCC細(xì)胞運(yùn)輸和處理 | 查看詳情 |
| 2 | 其他海外品牌代理 | 查看詳情 |
| 3 | ATCC代理 | 查看詳情 |
| 4 | 購(gòu)買(mǎi)須知 | 查看詳情 |
| 5 | 訂購(gòu)流程 | 查看詳情 |
| 梅經(jīng)理 | 17280875617 | 1438578920 |
| 胡經(jīng)理 | 13345964880 | 2438244627 |
| 周經(jīng)理 | 17757487661 | 1296385441 |
| 于經(jīng)理 | 18067160830 | 2088210172 |
| 沈經(jīng)理 | 19548299266 | 2662369050 |
| 李經(jīng)理 | 13626845108 | 972239479 |
